SecBot SecBot
SECBOTREPLAY Home › Report › BMY

BMY · A federal court granted a motion to remand a civil case involving…

Bristol-Myers Squibb Company et al. · COURT-RULING filed Feb 25, 2026 at 19:00 ET

At the news

NEUTRALIMPACT 3/10

COURT-RULING filed Feb 25, 2026 at 19:00 ET

A federal court granted a motion to remand a civil case involving Bristol-Myers Squibb (BMY) back to New Jersey state court, ruling that the addition of a nondiverse plaintiff destroyed federal diversity jurisdiction and that remand was appropriate under procedural fairness and judicial economy grounds. The underlying dispute stems from allegations of fraud related to the rezoning of a former BMS property.

  • The U.S. District Court for the District of New Jersey granted plaintiffs' motion to remand the case to state court due to loss of diversity jurisdiction after the addition of New Jersey resident John Hart as a plaintiff.
  • The case involves allegations of fraud and conspiracy related to the 2019 rezoning of a 433-acre BMS property in Hopewell, NJ, which enabled its sale to a third party.
  • Plaintiffs allege BMS and its broker misrepresented that no offers existed under existing zoning, prompting the township to rezone the property, which benefited subsequent buyer BeOne Medicines.
  • No final judgment on the merits has been reached; the ruling is purely procedural, returning the case to state court for further litigation.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access